CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
GD2-CART01 for relapsed or refractory high-risk neuroblastoma
F Del Bufalo, B De Angelis, I Caruana… - … England Journal of …, 2023 - Mass Medical Soc
Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
Advancing therapy for neuroblastoma
B Qiu, KK Matthay - Nature Reviews Clinical Oncology, 2022 - nature.com
Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …
ranging from localized or spontaneously regressing to widely metastatic disease …
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas
(DMGs) are universally lethal paediatric tumours of the central nervous system. We have …
(DMGs) are universally lethal paediatric tumours of the central nervous system. We have …
[HTML][HTML] GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
Pediatric cancers often mimic fetal tissues and express proteins normally silenced
postnatally that could serve as immune targets. We developed T cells expressing chimeric …
postnatally that could serve as immune targets. We developed T cells expressing chimeric …
Metabolic challenges and interventions in CAR T cell therapy
Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma
Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have performed
poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated …
poorly in clinical trials for solid tumors due to heterogenous expression of tumor-associated …